Mechanisms of placental transfer for small molecules and biologics

Leslie Myatt PhD FRCOG Dept of Obstetrics and Gynecology Moore Institute of Nutrition and Wellness Oregon Health & Science University



I have no conflicts of interest

The placenta – not just a conduit







	6 weeks Term
Fetal/Placental Weight Ratio	0.18 7.23
Villous volume occupied by vessels (%)	2.7 28.4
Trophoblast Surface area (m ²)	0.08 12.5
Mean Trophoblast Thickness (µm) 18.9 4.1
Maternofetal Diffusion Distance (µm)	55.9 4.8

Placental Transport Mechanisms



Drug transporters in human placenta

Roles

- Control uptake and transport of drugs
- Protect critical tissues/cells from xenobiotics

Originally classified by function, now by sequence homology of genes

- Solute carrier (SLC) transporters
 - Mainly involved in uptake of substances (eg amino acids, SLC3, 7)
- ATP-binding cassette (ABC) transporters
 - Involved in efflux of substances

Expression changes across gestation and with drug-drug interactions, obstetric condition and single-nucleotide polymorphisms.

SLC transporters

- Secondary active and passive transport
- More than 400 transporters in over 60 families
- SLCO (Organic anion transporting polypeptide: OATP) family
- SLC22A (Organic cation transporter: OCT, organic cation transporter novel type (OCTN) and organic anion transporter: OAT)
- SLC29A (Equilibrative nucleotide transporter: ENT) family
- SLC47A (Multidrug and toxin extrusion: MATE) family

ABC transporters

- Highly conserved
- Use ATP hydrolysis for energy
- Originally identified as multidrug resistance factor (P-glycoprotein: P-gp)
- P-gp encoded by ABCB1 expressed in syncytiotrophoblast apical membrane transports cationic hydrophobic compounds
- 7 subgroups (ABCB, C and G are drug transporters)
- 2 nucleotide binding (NBD) and 2 transmembrane domains (TMD)

Localization of drug transporters in placenta



Yamashita M and Markert UR 2021

Factors influencing placental transport

- Molecular weight, charge
- Free vs bound
- Maternal and fetal plasma protein binding affinity and amount
- Lipid solubility, pH gradients
- Diffusion capacity
- Maternal and fetal blood flow
- Expression and localization of placental transporters
- Placental binding and metabolism
- Gestational age
- Placental energy generation (obesity, diabetes)
- Fetal sex

Evidence for Sexual Dimorphism in Placental Function

• Differences in gene expression, 1st trimester and term

- immune genes expressed at higher level in female placenta (JAK1, IL2RB, Clusterin, LTBP, CXCL1, IL1RL1, TNFR)
- Sexual dimorphism in placenta gene expression linked to failure of Xlinked inactivation (Gong et al JCI, 2018)
- Inflammatory, hypoxia, apoptosis and autophagy responses
- Antioxidant defenses, expression of antioxidant enzymes
- Fatty acid transporters and fatty acid oxidation
- Response to maternal adiposity and inflammatory status
- microRNA expression in normal pregnancy
- Aromatase expression with preeclampsia
- Linked to differences in outcome male vs female fetus

Sex-specific differences in immune response in pregnancy



10

Active transport of IgG in placenta



Of 5 antibody classes only IgG is transferred across the placenta via neonatal Fc receptor (FcRn)

FcRn shows pH dependence of IgG binding, high affinity at pH6.0 but 100x lower affinity at pH7.4

Thus FcRn is unable to bind IgG at the apical side of STB facing maternal blood

Placental transfer of IgG across gestation



Majority of IgG acquired by fetus in last 4 wks of gestation and exceeds maternal level by 20-30% at term Lower levels (esp IgG1 and IgG2) seen in preterm infants Low birth weight associated with impaired placental transfer of IgG1 and IgG2 subclasses Maternal age, weight, parity and type of delivery do not affect placental transfer

Placental transfer of IgG subclasses in late gestation





IgG1>IgG4>IgG3>IgG2

Palmeira P et al 2012

Factors limiting efficacy of placental transfer after maternal immunization

- Time between immunization during pregnancy and delivery
- Gestational age of fetus at birth
- Total maternal IgG level
- Maternal vaccine-specific IgG and IgG subclass concentrations
- Maternal pathologies such as hypergammaglobulinemia, HIV infection, placental injury with malaria, intrauterine growth restriction (IUGR)?

Glycosylation of IgGs



Conserved N-linked glycan at Asn 297 in 2nd IgG domain of heavy chain in Fc region affects structure and function Galactosylated antibodies are transferred preferentially due to enhanced binding to FcRn Maternal infection may alter glycosylation e.g. Fc-glycan profiles of SARS-Cov-2 infected individuals

Transfer of Anti-TNFα antibodies

- Infliximab and adalimumab are IgG1 antibodies and have preferential transfer starting at end of 2nd trimester – neonatal levels may exceed maternal levels and persist for up to 12 months
- Etanercept fusion protein with modified Fc portion that binds to $TNF\alpha$ has low capacity for transfer, minimal levels in fetus at birth
- Certolizumab (Fab conjugated to polyethylene glycol, PEG), an anti-TNF therapy missing the Fc portion, does not cross placenta and can be used throughout pregnancy



Transfer efficiency of plant and mammalian antibodies in primate placenta

Rosenberg YJ et al 2023

Summary

- Placenta is not simply a conduit, its function changes across gestation and with fetal sex and medical condition
- Placenta has evolved a range of transporters to handle molecules of a range of sizes to nourish but also protect the fetus
- Many factors influence placental transport
- Transfer of small molecules is effected by drug transporters
- IgG is transported via neonatal Fc receptor (FcRn)
- Glycosylation of IgG antibodies affects binding to FcRn and transport across the placenta



the production of the second ball

to any differ a stated

The second second